Genentech/Roche Deal History & Licensing Activity
Genentech/Roche is a large pharma headquartered in US. Over the past three years, Genentech/Roche has been involved in 10 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 19 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
6
Active Trials
19
Top Modality
Small Molecules
Focus Area
Hematological Malignancies
Genentech/Roche Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Genentech/Roche in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed bispecific antibody oncology asset | Earendil Labs | Bispecific Antibodies | Discovery | collaboration | Sep 24, 2026 |
| DUPAC novel-payload ADC programs | DualityBio | Other | Unknown | collaboration | Aug 28, 2026 |
| ExPERT GTx | Genentech | Cell Therapy | Unknown | license | Jul 21, 2026 |
| RNAi program | Genentech | Oligonucleotides | Preclinical | license | Feb 2, 2026 |
| Undisclosed | Genentech | Small Molecules | Preclinical | license | Jan 6, 2026 |
| Undisclosed | Genentech | Small Molecules | Phase 1 | license | Dec 30, 2025 |
Genentech/Roche Pipeline Focus
Therapeutic areas and modalities where Genentech/Roche is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Genentech/Roche Clinical Pipeline
Genentech/Roche has 19 active clinical trials across 6 development phases.
1
Phase 4
1
Not Applicable
2
Unknown
7
Phase 1
3
Phase 2
5
Phase 3
See How Your Asset Matches Genentech/Roche's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Genentech/Roche Licensing & Deal Activity
Genentech/Roche is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 10 deals over the past three years, Genentech/Roche ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Genentech/Roche include Hematological Malignancies (8 deals and trials), Other (5 deals and trials), Metabolic (4 deals and trials), and Solid Tumors (4 deals and trials). In terms of modality, Genentech/Roche has shown particular interest in small molecules, other, cell therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Genentech/Roche and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Genentech/Roche's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.